Journal
THESCIENTIFICWORLDJOURNAL
Volume 8, Issue -, Pages 909-919Publisher
HINDAWI LTD
DOI: 10.1100/tsw.2008.117
Keywords
cetuximab; epidermal growth factor receptor; Erbitux; head and neck cancer; lung cancer; targeted therapy
Categories
Funding
- NIH/NCI [CA125541-02, CA129501]
- American Lung Association
- V-Foundation
- Respiratory Health Association of Chicago
- Kate McMullen Foundation
- University of Chicago Cancer Research Center
- NATIONAL CANCER INSTITUTE [R01CA129501, R01CA125541] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cancers of the head and neck and of the lung are associated with high morbidity and mortality rates that have remained relatively unchanged for more than 3 decades, despite advances in radiation therapies and chemotherapies over the same time. It is generally believed that the efficacy of standard therapy regimens has reached a plateau for these cancers. The discovery of specific aberrant molecular signaling pathways in solid tumors has afforded promising new directions for newer targeted cancer therapeutics. Among these, the epidermal growth factor receptor (EGFR) shows promise as a therapeutic target. Clinical studies have demonstrated that this targeted approach provides clinically meaningful benefit. This article reviews EGFR-targeted therapies in use and in development, with a focus on the role of EGFR in the pathophysiology of head and neck and lung cancer, and new concepts being investigated to improve outcomes with these agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available